Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00095121 · ClinicalTrials.gov registry record · Phase 3

Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B

A Phase 3 study, sponsored by Gilead Sciences.

Completed
Registry status
Phase 3
Development phase
173
Enrollment target

NCT00095121: Completed Phase 3 study, sponsored by Gilead Sciences.

NCT00095121 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 173 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00095121, a Phase 3 study, has completed, sponsored by Gilead Sciences.

COMPLETED
Registry status
Phase 3
Development phase
173 participants
Enrollment target

Study Summary

The purpose of this study is to investigate the efficacy and safety of adefovir dipivoxil for the treatment of chronic hepatitis B in children and adolescents (age 2 to less than 18 years) following 48 weeks of placebo-controlled, double-blind treatment and following an additional 192 weeks of open-label adefovir dipivoxil treatment.

Primary Outcome

In the absence of biopsy data from these pediatric participants, this endpoint enables assessments of drug effect on viral replication and the underlying degree of inflammation in the liver.

Interventions

  • DRUG Lamivudine
  • DRUG Placebo (PLB)
  • DRUG Adefovir Dipivoxil (ADV)

Trial Details

FieldValue
Enrollment Target 173 participants
Start Date 2004-06
Est. Completion 2010-04
Phase Phase 3
Gilead Sciences

504 total trials

What the finished NCT00095121 record still lists

NCT00095121 is an interventional study that assigns participants to a tested intervention. The registered 173 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower).

The record links to 0 conditions, and to 3 interventions - of which Lamivudine is the first listed.

NCT00095121 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00095121 about?

NCT00095121 is a clinical study titled "Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B". The purpose of this study is to investigate the efficacy and safety of adefovir dipivoxil for the treatment of chronic hepatitis B in children and adolescents (age 2 to less than 18 years) following 48 weeks of placebo-controlled, double-blind treatment and following an additional 192 weeks of open-...

What is the current status of trial NCT00095121?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 173 participants. The study started on 2004-06. Estimated completion is 2010-04.

What interventions are being tested in trial NCT00095121?

The interventions under investigation include: Lamivudine (DRUG), Placebo (PLB) (DRUG), Adefovir Dipivoxil (ADV) (DRUG).

Who is sponsoring clinical trial NCT00095121?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00095121's enrollment target sits among peer trials

173 1445th of 2000 higher than 553 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05568719 · 173 participants · Phase 3

    Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

  • NCT07070115 · 173 participants · NA

    Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®

  • NCT07150832 · 173 participants · NA

    Efficacy of the I-CARE Digital Health Intervention

  • NCT01000259 · 174 participants

    Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00095121, the US trial registry maintained by the National Library of Medicine. NCT00095121 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.